Claris Bio
3 known investors
Claris Bio is a late-stage therapeutics company developing pharmacologic treatments for sight-threatening ophthalmic conditions with no or limited treatment options. Its lead candidate, CSB-001 (oremepermin alfa ophthalmic solution), targets limbal stem cell deficiency (LSCD), a blinding disease, with pivotal studies planned for 2027.
BiotechHealthtech
Investors · 3
Funding
SEC filings, press & company announcements$118M disclosed across 1 of 3 rounds · 2026
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Claris Bio do?
- Claris Bio is a late-stage therapeutics company developing pharmacologic treatments for sight-threatening ophthalmic conditions with no or limited treatment options. Its lead candidate, CSB-001 (oremepermin alfa ophthalmic solution), targets limbal stem cell deficiency (LSCD), a blinding disease, with pivotal studies planned for 2027.
- Who are Claris Bio's investors?
- Claris Bio's investors include RA Capital, Sofinnova Ventures, Novo Holdings.
- How much funding has Claris Bio raised?
- Claris Bio has disclosed $118M raised across 1 of its 3 known rounds.